These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

813 related articles for article (PubMed ID: 24037775)

  • 1. Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal.
    Eng C; Chang GJ; You YN; Das P; Xing Y; Delclos M; Wolff RA; Rodriguez-Bigas MA; Skibber J; Ohinata A; Gould S; Phillips J; Crane CH
    Cancer; 2013 Nov; 119(21):3769-75. PubMed ID: 24037775
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Review of anal cancer patients at the Ottawa hospital.
    Abunassar M; Reinders J; Jonker DJ; Asmis T
    Eur J Surg Oncol; 2015 May; 41(5):653-8. PubMed ID: 25776438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin-based combined modality therapy for anal carcinoma: a wider therapeutic index.
    Hung A; Crane C; Delclos M; Ballo M; Ajani J; Lin E; Feig B; Skibber J; Janjan N
    Cancer; 2003 Mar; 97(5):1195-202. PubMed ID: 12599225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Epidermoid carcinomas of anal canal treated with radiation therapy and concomitant chemotherapy (5-fluorouracil and cisplatin)].
    Deniaud-Alexandre E; Touboul E; Tiret E; Sezeur A; Hannoun L; Houry S; Huguet F; Pène F; Parc R; Schlienger M
    Cancer Radiother; 2006 Dec; 10(8):572-82. PubMed ID: 17110148
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemoradiotherapy of anal carcinoma: survival and recurrence in an unselected national cohort.
    Bentzen AG; Guren MG; Wanderås EH; Frykholm G; Tveit KM; Wilsgaard T; Dahl O; Balteskard L
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e173-80. PubMed ID: 22436791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II Study of Capecitabine in Substitution of 5-FU in the Chemoradiotherapy Regimen for Patients with Localized Squamous Cell Carcinoma of the Anal Canal.
    Oliveira SC; Moniz CM; Riechelmann R; Alex AK; Braghirolli MI; Bariani G; Nahas C; Hoff PM
    J Gastrointest Cancer; 2016 Mar; 47(1):75-81. PubMed ID: 26691173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Definitive radiotherapy for squamous cell carcinoma of the anal canal.
    Rabbani AN; Zlotecki RA; Kirwan J; George TJ; Morris CG; Rout WR; Mendenhall WM
    Am J Clin Oncol; 2010 Feb; 33(1):47-51. PubMed ID: 19704368
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of acute toxicity and quality of life after IMRT and concurrent chemotherapy for anal canal and perianal cancer.
    Han K; Cummings BJ; Lindsay P; Skliarenko J; Craig T; Le LW; Brierley J; Wong R; Dinniwell R; Bayley AJ; Dawson LA; Ringash J; Krzyzanowska MK; Moore MJ; Chen EX; Easson AM; Kassam Z; Cho C; Kim J
    Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):587-94. PubMed ID: 25194664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects of chemoradiotherapy for anal cancer in patients with HIV infection: oncological outcomes, immunological status, and the clinical course of the HIV disease.
    Fraunholz IB; Haberl A; Klauke S; Gute P; Rödel CM
    Dis Colon Rectum; 2014 Apr; 57(4):423-31. PubMed ID: 24608297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour- and treatment-related colostomy rates following mitomycin C or cisplatin chemoradiation with or without maintenance chemotherapy in squamous cell carcinoma of the anus in the ACT II trial.
    Glynne-Jones R; Kadalayil L; Meadows HM; Cunningham D; Samuel L; Geh JI; Lowdell C; James R; Beare S; Begum R; Ledermann JA; Sebag-Montefiore D;
    Ann Oncol; 2014 Aug; 25(8):1616-22. PubMed ID: 24827136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Squamous-cell carcinoma of the anal canal: predictors of treatment outcome.
    Roohipour R; Patil S; Goodman KA; Minsky BD; Wong WD; Guillem JG; Paty PB; Weiser MR; Neuman HB; Shia J; Schrag D; Temple LK
    Dis Colon Rectum; 2008 Feb; 51(2):147-53. PubMed ID: 18180997
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Twenty-five-year experience with radical chemoradiation for anal cancer.
    Tomaszewski JM; Link E; Leong T; Heriot A; Vazquez M; Chander S; Chu J; Foo M; Lee MT; Lynch CA; Mackay J; Michael M; Tran P; Ngan SY
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):552-8. PubMed ID: 22019078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concomitant chemoradiotherapy with Cisplatin plus 5-Fluorouracil for anal squamous cell carcinoma.
    El-Hadaad HA; Wahba HA; Roshdy S
    J Gastrointest Cancer; 2015 Jun; 46(2):156-60. PubMed ID: 25810165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up.
    Psyrri A; Kwong M; DiStasio S; Lekakis L; Kassar M; Sasaki C; Wilson LD; Haffty BG; Son YH; Ross DA; Weinberger PM; Chung GG; Zelterman D; Burtness BA; Cooper DL
    J Clin Oncol; 2004 Aug; 22(15):3061-9. PubMed ID: 15284256
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase II study of cisplatin and 5-fluorouracil with concurrent hyperfractionated thoracic radiation for locally advanced non-small-cell lung cancer: a preliminary report from the Okayama Lung Cancer Study Group.
    Segawa Y; Ueoka H; Kiura K; Kamei H; Tabata M; Sakae K; Hiraki Y; Kawahara S; Eguchi K; Hiraki S; Harada M
    Br J Cancer; 2000 Jan; 82(1):104-11. PubMed ID: 10638975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Squamous cell carcinoma of the anal margin: the university of Florida experience.
    Balamucki CJ; Zlotecki RA; Rout WR; Newlin HE; Morris CG; Kirwan JM; George TJ; Mendenhall WM
    Am J Clin Oncol; 2011 Aug; 34(4):406-10. PubMed ID: 20881476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.
    James RD; Glynne-Jones R; Meadows HM; Cunningham D; Myint AS; Saunders MP; Maughan T; McDonald A; Essapen S; Leslie M; Falk S; Wilson C; Gollins S; Begum R; Ledermann J; Kadalayil L; Sebag-Montefiore D
    Lancet Oncol; 2013 May; 14(6):516-24. PubMed ID: 23578724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Squamous cell carcinoma antigen: a potentially useful prognostic marker in squamous cell carcinoma of the anal canal and margin.
    Williams M; Swampillai A; Osborne M; Mawdsley S; Hughes R; Harrison M; Harvey R; Glynne-Jones R;
    Cancer; 2013 Jul; 119(13):2391-8. PubMed ID: 23576077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concomitant low-dose cisplatin and three-dimensional conformal radiotherapy for locally advanced squamous cell carcinoma of the head and neck: Analysis of survival and toxicity.
    Lau H; Brar S; Hao D; MacKinnon J; Yee D; Gluck S
    Head Neck; 2006 Mar; 28(3):189-96. PubMed ID: 16265658
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity.
    Mitchell MP; Abboud M; Eng C; Beddar AS; Krishnan S; Delclos ME; Crane CH; Das P
    Am J Clin Oncol; 2014 Oct; 37(5):461-6. PubMed ID: 23466576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 41.